STAVUDINE
Clinical safety rating: safe
Animal studies have demonstrated safety
Nucleoside reverse transcriptase inhibitor; intracellularly phosphorylated to active triphosphate which competitively inhibits HIV-1 reverse transcriptase and causes DNA chain termination.
| Metabolism | Stavudine is not significantly metabolized; approximately 40% of the dose is excreted unchanged in the urine via renal tubular secretion and glomerular filtration. Minor intracellular phosphorylation to active triphosphate. |
| Excretion | Renal (approximately 70% unchanged, 30% as metabolites); biliary/fecal minimal. |
| Half-life | Terminal elimination half-life is 1.0–1.6 hours in adults; intracellular active triphosphate half-life is 3.5–7 hours, supporting twice-daily dosing. |
| Protein binding | Negligible (<5%) binding to plasma proteins. |
| Volume of Distribution | 0.5–1.0 L/kg, indicating distribution into total body water. |
| Bioavailability | Oral: 86.4% (range 79–99%) in adults; high and consistent. |
| Onset of Action | Oral: Peak plasma concentration achieved in 1–1.5 hours; antiviral effect begins within 1–2 days. |
| Duration of Action | Duration of antiviral effect persists for 12–24 hours based on intracellular triphosphate levels; dosing every 12 hours maintains therapeutic effect. |
| Molecular Weight | 224.24 |
30 mg orally every 12 hours (for weight ≥60 kg: 40 mg every 12 hours)
| Dosage form | FOR SOLUTION |
| Renal impairment | CrCl >50 mL/min: no adjustment; CrCl 26-50 mL/min: 15 mg every 12 hours (≥60 kg: 20 mg every 12 hours); CrCl 10-25 mL/min: 15 mg every 24 hours (≥60 kg: 20 mg every 24 hours); CrCl <10 mL/min or hemodialysis: 15 mg every 24 hours (≥60 kg: 20 mg every 24 hours, administer after dialysis) |
| Liver impairment | Child-Pugh Class A or B: no dose adjustment; Child-Pugh Class C: reduce dose or consider alternative therapy (no specific dosing guidelines available) |
| Pediatric use | For birth to 13 days: 0.5 mg/kg/dose every 12 hours; for 14 days to <30 kg: 1 mg/kg/dose every 12 hours; for ≥30 kg: 30 mg every 12 hours (maximum 40 mg every 12 hours for weight ≥60 kg) |
| Geriatric use | Consider age-related renal impairment; monitor renal function and adjust dose accordingly; no specific dose adjustments based solely on age |
| 1st trimester | Use only if benefit outweighs risk; associated with mitochondrial toxicity and lactic acidosis. |
| 2nd trimester | Use if clearly needed; monitor for lactic acidosis and hepatic steatosis. |
| 3rd trimester | Use if clearly needed; monitor for lactic acidosis and hepatic steatosis. |
Clinical note
Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.
| Placental transfer | Stavudine crosses the placenta readily; cord blood concentrations are approximately equal to maternal serum concentrations. |
| Breastfeeding | Stavudine is excreted into human breast milk at low concentrations. In HIV-infected women, breastfeeding is not recommended to avoid postnatal transmission of HIV. |
■ FDA Black Box Warning
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including stavudine. Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. Co-administration of stavudine with didanosine is contraindicated because of increased risk of toxicity.
| Common Effects | Peripheral neuropathy |
| Serious Effects |
Hypersensitivity to stavudine or any component of the formulationConcomitant use with didanosine (increased risk of lactic acidosis and hepatic steatosis)
| Precautions | Lactic acidosis/severe hepatomegaly with steatosis, Pancreatitis (especially in combination with didanosine), Peripheral neuropathy, Lipodystrophy, Hepatic impairment, Renal impairment (dose adjustment required), Immune reconstitution syndrome |
Loading safety data…
| Lactation Rating |
| L4 (Possibly Hazardous) |
| Teratogenic Risk | Stavudine is classified as FDA Pregnancy Category C. Animal studies have shown evidence of embryotoxicity and increased incidence of fetal skeletal variations at doses producing maternal toxicity. Human data are limited but have not shown a clear increase in major birth defects above background. There is a risk of mitochondrial toxicity in fetuses exposed in utero, potentially manifesting as neurological disorders or lactic acidosis. First trimester exposure carries theoretical risk; however, antiretroviral therapy is generally continued during pregnancy to prevent vertical transmission. The risk-benefit ratio favors use when indicated. Second and third trimester exposure: no specific teratogenic effects documented, but mitochondrial dysfunction may be exacerbated. |
| Fetal Monitoring | Monitor maternal complete blood count, hepatic function, and lactic acid levels regularly due to risk of lactic acidosis and hepatotoxicity. Assess for signs of peripheral neuropathy. Fetal monitoring includes routine prenatal ultrasound to assess growth and anatomy. In third trimester, non-stress testing or biophysical profile may be considered if there are concerns about placental insufficiency. Newborns should be monitored for signs of mitochondrial toxicity (e.g., hypotonia, seizures, respiratory distress) and have baseline and follow-up lactate levels. |
| Fertility Effects | Animal studies have shown no significant adverse effects on fertility at clinically relevant doses. In humans, stavudine has not been associated with impaired fertility. However, HIV infection itself can affect fertility, and its treatment may restore health. There is no evidence of long-term impact on male or female reproductive function. |
| Food/Dietary |
| No significant food interactions. Stavudine can be taken with or without food. High-fat meals may slightly reduce absorption but not clinically significant. Avoid alcohol due to increased risk of liver toxicity. |
| Clinical Pearls | Stavudine is associated with mitochondrial toxicity, including lactic acidosis and severe hepatomegaly with steatosis, especially in women, obesity, and prolonged nucleoside therapy. Peripheral neuropathy is dose-dependent and may require dose reduction or discontinuation. Avoid use with didanosine or hydroxyurea due to increased toxicity risk. Monitor for lipodystrophy and hyperlipidemia. Stavudine is not recommended as first-line therapy due to toxicity concerns; it is primarily used when other options are not available. |
| Patient Advice | Take stavudine exactly as prescribed, usually every 12 hours, with or without food. · Do not miss doses; if you do, take it as soon as you remember unless it is almost time for the next dose; do not double the next dose. · Report symptoms of lactic acidosis (unusual tiredness, muscle pain, trouble breathing, stomach pain with nausea/vomiting, cold feeling, fast/irregular heartbeat) or liver problems (dark urine, yellowing eyes/skin, right upper stomach pain) immediately. · Stavudine can cause numbness, tingling, or pain in hands/feet (peripheral neuropathy); notify your doctor if these occur. · Use effective contraception during treatment as stavudine may harm an unborn baby if used during pregnancy. · Do not stop stavudine without consulting your doctor; sudden discontinuation may lead to worsening HIV infection. · Inform your doctor about all other medications, including over-the-counter drugs and supplements, to avoid interactions. |